On November 5, 2019 OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported it will present a poster highlighting a safety and biomarker analysis on its lead product candidate, TAVO, at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland (Press release, OncoSec Medical, NOV 5, 2019, View Source [SID1234550357]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis," will be presented by author Alain Algazi, MD on Saturday, November 9th from 12:35 p.m. – 2:05 p.m. and from 7:00 p.m. – 8:30 p.m. Eastern Time.

The SITC (Free SITC Whitepaper) abstract titles are listed on the conference website under Abstracts at View Source